Lo An-Chi, Kleer Celina G, Banerjee Mousumi, Omar Sherif, Khaled Hussein, Eissa Saad, Hablas Ahmed, Douglas Julie A, Alford Sharon H, Merajver Sofia D, Soliman Amr S
Department of Epidemiology, University of Michigan School of Public Health, 109 Observatory Street, Ann Arbor, MI 48109, USA.
Breast Cancer Res Treat. 2008 Nov;112(1):141-7. doi: 10.1007/s10549-007-9833-z. Epub 2007 Dec 4.
Inflammatory breast cancer (IBC) is a lethal form of breast cancer with unknown etiology. A higher frequency of IBC and a more aggressive IBC phenotype was reported in Egypt than in the United States. This difference in disease frequency and presentation might be related to molecular epidemiologic factors.
We used tumor blocks and demographic, epidemiologic, and clinical data of 48 IBC patients from Egypt and 12 patients from the United States. We counted tumor emboli in tumors before and after immunohistochemical staining with lymphatic vessel endothelial receptor-1 (LYVE-1), and measured the expression of RhoC GTPase protein in the two groups.
Erythema, edema, and peau d'orange were found in 77% of the Egyptian patients as compared with 29% found in the US patients (P=0.02). The number of tumor emboli was significantly higher in tumors from Egypt (mean+/-SD, 14.1+/-14.0) than in the tumors from the United States (5.0+/-4.0, P=0.01). The number of tumor emboli in LYVE-1 positive vessels was higher in tumors from Egypt (3.5+/-2.8) than tumors from the United States (1.6+/-0.5, P=0.15). We detected a high level of RhoC in 87% of the tumors from Egypt and 14% of the tumors from the United States (P=0.0003).
Patients from Egypt have a more aggressive form of IBC than those in the United States. Our analysis of IBC patients shows that distinct molecular phenotypes can be found when these two study populations are compared. Future studies should explore the epidemiologic and environmental exposures and the genetic factors that might lead to the different clinical and molecular features of IBC in patients from these two countries.
炎性乳腺癌(IBC)是一种病因不明的致命性乳腺癌。据报道,埃及的IBC发病率高于美国,且其IBC表型更具侵袭性。疾病发病率和表现的这种差异可能与分子流行病学因素有关。
我们使用了来自埃及的48例IBC患者和来自美国的12例患者的肿瘤组织块以及人口统计学、流行病学和临床数据。我们在使用淋巴管内皮受体-1(LYVE-1)进行免疫组化染色前后对肿瘤中的肿瘤栓子进行计数,并测量两组中RhoC GTPase蛋白的表达。
77%的埃及患者出现红斑、水肿和橘皮样皮肤改变,而美国患者中这一比例为29%(P=0.02)。埃及肿瘤中的肿瘤栓子数量显著高于美国肿瘤(均值±标准差,14.1±14.0比5.0±4.0,P=0.01)。埃及肿瘤中LYVE-1阳性血管中的肿瘤栓子数量高于美国肿瘤(3.5±2.8比1.6±0.5,P=0.15)。我们在87%的埃及肿瘤和14%的美国肿瘤中检测到高水平的RhoC(P=0.0003)。
埃及患者的IBC形式比美国患者的更具侵袭性。我们对IBC患者的分析表明,比较这两个研究人群时可以发现不同的分子表型。未来的研究应探索可能导致这两个国家患者IBC临床和分子特征不同的流行病学和环境暴露因素以及遗传因素。